Sarepta Therapeutic (SRPT) Story Remains Intact, Needham & Company Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Baird Downgrades Sarepta Therapeutic (SRPT) to Neutral
October 28, 2014 6:46 AM EDTBaird downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Neutral with a price target of $21.00 (from $53.00).
Analyst Brian Skorney said, "Sarepta's regulatory update casts uncertainty around both the timeline for eteplirsen NDA submission and the fundamental underpinning of the drug's mechanism: dystrophin... More
Stifel Downgrades Sarepta Therapeutic (SRPT) to Hold
October 27, 2014 1:04 PM EDTStifel downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Hold and removed its price target (prior $46).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $23.56 yesterday.
... MoreJMP Securities Downgrades Sarepta Therapeutic (SRPT) to Market Perform
October 27, 2014 11:41 AM EDTJMP Securities downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $23.56 yesterday.
... MoreProsensa (RNA) Gains as Sarepta's (SRPT) Eteplirsen NDA Pushed Back
October 27, 2014 7:18 AM EDTProsensa Holding N.V. (NASDAQ: RNA) gained pre-market Monday after competitor Sarepta Therapeutics (NASDAQ: SRPT) announced the FDA requires additional data as part of the NDA submission for eteplirsen.
... MoreSarepta Therapeutics (SRPT) Reports More Data Needed for Eteplirsen NDA Submission
October 27, 2014 7:05 AM EDTSarepta Therapeutics (NASDAQ: SRPT) provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).
In meeting minutes received last week from a Type B Pre-NDA meeting that took place in September 2014, the FDA provided updated guidance regarding the specific data to be included as part of, or at the time of, Sareptas NDA submission. The guidance states that additional data are now required as part of... More
